Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 7, 2007, Pages 1382-1386

  Stepanov, Irina ^a   Hecht, Stephen S ^a   Lindgren, Bruce ^a   Jacob III, Peyton ^b   Wilson, Margaret ^b   Benowitz, Neal L ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; BIOLOGICAL MARKER; COTININE; NICOTINE; TOBACCO SMOKE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CIGARETTE SMOKING; CORRELATION FUNCTION; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG URINE LEVEL; EUROPEAN AMERICAN; FEMALE; GENDER; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VALIDATION STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; COTININE; ENDPOINT DETERMINATION; ENVIRONMENTAL EXPOSURE; FEMALE; GANGLIONIC STIMULANTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INDICATORS AND REAGENTS; INHALATION EXPOSURE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NAILS; NICOTINE; NITROSAMINES; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 34447507999     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0145     Document Type: Article

References (43)

1. IARC. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon (France): IARC; 2004.
2. World Health Organization. Tobacco or health: a global status report. Geneva: WHO; 1997. pp. 10-48.
3. Peto R, Lopez AD, Boreham J, et al. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
4. Benowitz NL, Jacob P, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
5. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204.
6. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
7. DeLeon J, Diaz FJ, Rogers T, et al. Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke. J Clin Psychopharmacol 2002;22:496-501.
8. Jarvis MJ, Primatesta P, Erens B, et al. Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates. Nicotine Tob Res 2003;5:349-55.
9. Heinrich J, Hoelscher B, Seiwert M, et al. Nicotine and cotinine in adults' urine: the German environmental survey 1998. J Expo Anal Environ Epidemiol 2005;15:74-80.
10. Jacqz-Aigrain E, Zhang D, Maillard G, et al. Maternal smoking during pregnancy and nicotine and cotinine concentrations in maternal and neonatal hair. Br J Obstet Gynaecol 2002;109:909-11.
11. Chan D, Caprara D, Blanchette P, et al. Recent developments in meconium and hair testing methods from the confirmation of gestational exposures to alcohol and tobacco smoke. Clin Biochem 2004;37:429-38.
12. Al-Delaimy WK, Crane J, Woodward A. Passive smoking in children: effect of avoidance strategies at home as measured by hair nicotine levels. Arch Environ Health 2001;56:117-22.
13. Matt GE, Quintana PJE, Liles S, et al. Evaluation of urinary trans-3′-hydroxycotinine as a biomarker of children's environmental tobacco smoke exposure. Biomarkers 2006;11:507-23.
14. St. Charles FK, Krautter GR, Dixon M, Mariner DC. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. Psychopharmacologia 2006;189:345-54.
15. Kim I, Darwin WD, Huestis MA. Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3′-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. J Chromatogr B 2005;814:233-40.
16. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-9.
17. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
18. Hecht SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
19. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
20. Carmella SG, Akerkar S, Richie JP, Jr., et al. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995;4:635-42.
21. Anderson KE, Carmella SG, Ming Ye, et al. Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke in their homes. J Natl Cancer Inst 2001;93:378-81.
22. Hecht SS, Ming Ye, Carmella SG, et al. Metabolites of a tobacco-specific lung carcinogen in the urine of elementary school-aged children. Cancer Epidemiol Biomarkers Prev 2001;10:1109-16.
23. Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-96.
24. Hecht SS, Carmella SG, Ye M, et al. Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res 2002;62:129-34.
25. Carmella SG, Han S, Villalta PW, et al. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' blood. Cancer Epidemiol Biomarkers Prev 2005;14:2669-72.
26. Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994;56:483-93.
27. Stepanov I, Feuer R, Jensen J, et al. Mass spectrometric quantitation of nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human toenails. Cancer Epidemiol Biomarkers Prev 2006;15:2378-83.
28. Palmeri A, Pichini S, Pacifici R, et al. Drugs in nails. Physiology, pharmacokinetics, and forensic toxicology. Clin Pharmacokinet 2000;38:95-110.
29. Hecht SS, Lin D, Castonguay A. Effects of α-deuterium substitution on the mutagenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 1983;4:305-10.
30. Hecht SS, Young R, Chen CB. Metabolism in the F344 rat of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Cancer Res 1980;40:4144-50.
31. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72.
32. Jacob P III, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr 1981;222:61-70.
33. Benowitz NL, Jacob P III, Bernert JT, et al. Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomarkers Prev 2005;14:1376-83.
34. Al-Delaimy WK, Mahoney GN, Speizer FE, et al. Toenail nicotine levels as a biomarker of tobacco smoke exposure. Cancer Epidemiol Biomarkers Prev 2002;11:1400-04.
35. Al-Delaimy WK. Hair as biomarker for exposure to tobacco smoke. Tob Control 2002;11:176-82.
36. Joseph AM, Hecht SS, Murphy SE, et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev 2005;14:2963-68.
37. Thun MJ, Heath CW. Changes in mortality from smoking in two American Cancer Society prospective studies since 1959. Prev Med 1997;26:422-6.
38. Kandel DB, Chen K. Extent of smoking and nicotine dependence in the United States: 1991-1993. Nicotine Tob Res 2000;2:263-74.
39. Murray RP, Connett JE, Buist AS, et al. Experience of Black participants in the Lung Health Study smoking cessation intervention program. Nicotine Tob Res 2001;3:375-82.
40. Etter JF, Duc TV, Perneger TV. Saliva cotinine levels in smokers and nonsmokers. Am J Epidemiol 2000;151:251-8.
41. Caraballo RS, Giovino GA, Pechacek TF, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998;280:135-9.
42. Muscat JE, Djordjevic MV, Colosimo S, et al. Racial differences in exposure and glucuronidation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Cancer 2005;103:1420-6.
43. Murphy SE, Link KA, Jensen J, et al. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev 2004;13:1617-23.